Short Interest in iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) Declines By 45.3%

by · The Markets Daily

iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA – Get Free Report) was the recipient of a large decline in short interest in June. As of June 15th, there was short interest totaling 22,477 shares, a decline of 45.3% from the May 31st total of 41,071 shares. Currently, 0.4% of the shares of the stock are short sold. Based on an average trading volume of 28,094 shares, the short-interest ratio is presently 0.8 days.

Institutional Investors Weigh In On iShares Genomics Immunology and Healthcare ETF

An institutional investor recently raised its stake in iShares Genomics Immunology and Healthcare ETF stock. Ameriprise Financial Inc. grew its position in iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA – Free Report) by 8.4% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 71,473 shares of the company’s stock after buying an additional 5,540 shares during the quarter. Ameriprise Financial Inc. owned 1.42% of iShares Genomics Immunology and Healthcare ETF worth $1,688,000 as of its most recent SEC filing.

iShares Genomics Immunology and Healthcare ETF Stock Down 0.4%

Shares of NYSEARCA:IDNA traded down $0.14 during trading on Wednesday, reaching $33.61. 131,184 shares of the company traded hands, compared to its average volume of 43,202. The firm has a market capitalization of $183.17 million, a PE ratio of 14.76 and a beta of 0.96. iShares Genomics Immunology and Healthcare ETF has a 52 week low of $20.56 and a 52 week high of $33.95. The company’s 50 day moving average is $30.03 and its two-hundred day moving average is $29.16.

About iShares Genomics Immunology and Healthcare ETF

(Get Free Report)

The iShares Genomics Immunology and Healthcare ETF (IDNA) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund tracks a market-cap-selected and -weighted index of global stocks involved in genomics, immunology, and bioengineering. IDNA was launched on Jun 11, 2019 and is managed by BlackRock.

Read More